Ivanmed has announced the release of the Juliette Armand AMESON Exo Fusion Range in UK.
Launching at the Aesthetics Conference and Exhibition (ACE) 2026, the range features a mesotherapy formulation combining exosomes and polydeoxyribonucleotide (PDRN) polynucleotides, which Ivanmed shares are designed to support skin regeneration.
The company further notes that exosomes aim to act as cellular messengers, stimulating collagen and elastin synthesis, while the PDRN polynucleotides are designed to enhance hydration and tissue repair. Ivanmed notes that the formulation incorporates two exosome sources, from Centella asiatica and Lactobacillus, claiming complementary mechanisms of action. The company adds that the range is compatible with professional microneedling protocols.
Simon Ringer, sales director at Ivanmed, commented, “With AMESON Exo Fusion, we’re giving clinics a truly next-generation regenerative treatment. Its unique dual-exosome and PDRN polynucleotide formulation delivers exceptional clinical results, while its compatibility with microneedling and strong treatment margins makes it an outstanding addition for practices focused on growth and patient satisfaction.”